Armata Pharmaceuticals, Inc. (ARMP)

[gimmeshelter]

I believe it definitely could, possibly within a year. They've only saved 9 out of 11 people unresponsive to antibiotics, with the other two dying from septic shock unrelated to the treatment. All treatments have been well tolerated by patients. They've brought people back from death's doorstep with one guy in a coma before being treated and saved. WHO predicts millions of deaths by 2050 due to AB resistant infections. Low float, possible VA funding to coincide with announced collaboration, likely repeat of AU funding and a great candidate for partner or buyout. All this with only Phase 1 in the books. Don't be surprised if meeting with FDA this summer leads to path for approval after P2. What's left to prove? Are there any issues to address for REMS when phages are directly attracted to infection, then consume the infection and naturally leave the body with no adverse effects? (excellent videos on youtube explaining this). And this expanded report of recent news released today: https://finance.yahoo.com/news/aphb-successful-case-reports-presented-144500026.html